Fulgent Genetics COO Xie Jian disposes of $23,747 in company stock

Fulgent Genetics President and COO Jian Xie sold 1,193 shares of the company's common stock for a combined value of $23,747 on August 27, 2026. The price per share ranged between $19.83 and $20.00, with a weighted average sale price of $19.9053. This move was made to fulfill tax withholding obligations stemming from the vesting of restricted stock units granted to Xie on February 26, 2024.

Over the last six months, the stock price increased by nearly 28%, although it has declined by 25% year-to-date. Current analysis suggests that Fulgent Genetics (FLGT) is undervalued, trading at $19.61 with a market capitalization of $540 million. As of the latest report, Xie still holds a total of 362,051 shares directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he is a member of the investment committee.

Xie has explicitly disclaimed any beneficial interest in these shares, aside from any financial stake. Despite a 4% revenue increase compared to the same quarter last year and a 20% rise from the first quarter, Fulgent Genetics fell short of market expectations in its recent second-quarter report. The company reported an adjusted loss per share of $0.58, surpassing the anticipated loss of $0.44.

Revenue for the quarter was $85.4 million, below the projected $91.77 million. Challenges were attributed to billing system issues impacting collections, leading to a revised full-year outlook. In response to these events, Fulgent Genetics has acknowledged the positive contributions of Bako Diagnostics and StrataDx in driving revenue growth.